Evidence map›Paper›PMID 34745970›Full record

ReviewFrontiers in oncology2021

m6A Modification in Non-Coding RNA: The Role in Cancer Drug Resistance.

Chen Chen, Yuying Guo, Yaxin Guo, Xiaoke Wu, Chaohua Si, Yanxin Xu, Qiaozhen Kang, Zhenqiang Sun

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. NCell death discovery · 2022
    Article
  19. mBioengineered · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Chen ChenDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yuying GuoDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yaxin GuoHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Xiaoke WuDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chaohua SiSchool of Life Science, Zhengzhou University, Zhengzhou, China.
Yanxin XuDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Qiaozhen KangSchool of Life Science, Zhengzhou University, Zhengzhou, China.
Zhenqiang SunDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhengzhou University · CNFirst Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer drug resistance has always been a major difficulty in cancer therapy. In the face of drug pressure, resistant cancer cells show complex molecular mechanisms including epigenetic changes to maintain survival. Studies prove that cancer cells exhibit abnormal m6A modification after acquiring drug resistance. m6A modification in the target RNA including non-coding RNA can be a controller to determine the fate and metabolism of RNA by regulating their stability, subcellular localization, or translation. In particular, m6A-modified non-coding RNA plays multiple roles in multiple drug-resistant cancer cells, which can be a target for cancer drug resistance. Here, we provide an overview of the complex regulatory mechanisms of m6A-modified non-coding RNA in cancer drug resistance, and we discuss its potential value and challenges in clinical applications.

Indexed as

cancer drug resistancecircRNAlncRNAm6A modificationmiRNA

Identifiers

PMID34745970
PMCPMC8564146
OpenAlexW3205393837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.